Kanaka CYP2C19 Gene Polymorphism

ʻO ka wehewehe pōkole:

Hoʻohana ʻia kēia pahu no ka ʻike in vitro qualitative o ka polymorphism o CYP2C19 genes CYP2C19*2 (rs4244285, c.681G>A), CYP2C19*3 (rs4986893, c.636G>A), CYP2C19*248 (rs4244285, c.681G>A), CYP2C19*3 (rs4986893, c.636G>A), CYP2C19*248 (rs4012,608). >T) i ka DNA genomic o nā laʻana koko holoʻokoʻa kanaka.


Huahana Huahana

Huahana Huahana

Inoa mea kūʻai

HWTS-GE012A-Human CYP2C19 Gene Polymorphism Detection Kit (Fluorescence PCR)

Palapala

CE/TFDA

Epidemiology

ʻO CYP2C19 kekahi o nā enzyme metabolizing lāʻau nui i ka ʻohana CYP450.ʻO ka nui o nā substrates endogenous a ma kahi o 2% o nā lāʻau lapaʻau e hoʻololi ʻia e CYP2C19, e like me ka metabolism o ka antiplatelet aggregation inhibitors (e like me clopidogrel), proton pump inhibitors (omeprazole), anticonvulsants, a pēlā aku. lāʻau pili.ʻO kēia mau helu hoʻololi o *2 (rs4244285) a me *3 (rs4986893) ke kumu i ka nalowale o ka hana enzyme i hoʻopaʻa ʻia e ka CYP2C19 gene a me ka nāwaliwali o ka hiki ke substrate metabolic, a hoʻonui i ka neʻe ʻana o ke koko, i mea e hoʻopilikia ai i ka lāʻau lapaʻau. koko koko.*17 (rs12248560) hiki ke hoʻonui i ka hana enzyme i hoʻopaʻa ʻia e CYP2C19 gene, ka hana ʻana o nā metabolites ikaika, a hoʻonui i ka pale ʻana i ka platelet aggregation a hoʻonui i ka pilikia o ke koko.No ka poʻe me ka lohi o ka metabolism o nā lāʻau lapaʻau, ʻo ka lawe ʻana i nā maʻi maʻamau no ka manawa lōʻihi e hoʻoulu ai i nā hopena koʻikoʻi a me nā hopena ʻaoʻao: ʻo ka nui o ka pōʻino o ka ate, ka pōʻino o ka ʻōnaehana hematopoietic, ka pōʻino o ka ʻōnaehana nerve waena, etc., hiki ke alakaʻi i ka make i nā hihia koʻikoʻi.Wahi a nā ʻokoʻa o kēlā me kēia kanaka i ka lāʻau lapaʻau e pili ana, ua māhele ʻia i ʻehā phenotypes, ʻo ia hoʻi ka ultra-fast metabolism (UM,*17/*17,*1/*17), fast metabolism (RM,*1/*1 ), ka hoʻokele waena (IM, *1/*2, *1/*3), ka hoʻokaʻawale lohi (PM, *2/*2, *2/*3, *3/*3).

Kanal

FAM CYP2C19*2
CY5 CYP2C9*3
ROX CYP2C19*17
VIC/HEX IC

Nā ʻāpana ʻenehana

Waihona Ka wai: ≤-18 ℃
Kau-ola 12 mahina
ʻAno Hoʻohālike Ke koko anticoagulated EDTA hou
CV ≤5.0%
LoD 1.0ng/μL
kikoo ʻAʻohe hoʻololi keʻa me nā kaʻina like ʻole (CYP2C9 gene) i loko o ka genome kanaka.ʻO nā hoʻololi ʻana o CYP2C19*23, CYP2C19*24 a me CYP2C19*25 mau wahi ma waho o ka ʻike ʻike o kēia pahu ʻaʻohe hopena i ka hopena ʻike o kēia pahu.
Nā mea hana pili Hoʻohana ʻia Biosystems 7500 Pūnaehana PCR manawa maoli

Hoʻohana ʻia ʻo Biosystems 7500 Fast Real-Time PCR Systems

QuantStudio®5 Pūnaehana PCR Manawa maoli

SLAN-96P Pūnaehana PCR Manawa maoli

LightCycler®480 Pūnaehana PCR manawa maoli

LineGene 9600 Plus Pūnaehana ʻike PCR manawa maoli

MA-6000 ʻOiaʻiʻo ka nui o ka wela wela

BioRad CFX96 Pūnaehana PCR Manawa maoli

BioRad CFX Opus 96 Pūnaehana PCR Manawa maoli

Holo Hana

Manaʻo ʻia ka hoʻoulu ʻana: Macro & Micro-Test General DNA/RNA Kit (HWTS-3019) (hiki ke hoʻohana ʻia me Macro & Micro-Test Automatic Nucleic Acid Extractor (HWTS-EQ011)) na Jiangsu Macro & Micro-Test Med-Tech Co., Ltd. Pono e unuhi ʻia ka unuhi e like me nā kuhikuhi.ʻO 200μL ka nui o ka laʻana, a ʻo ka nui elution i ʻōlelo ʻia he 100μL.

Manaʻo ʻia ka mea hoʻoheheʻe: Wizard® Genomic DNA Purification Kit (Catalog No.: A1120) na Promega, Nucleic Acid Extraction a i ʻole Purification Reagent (YDP348) na Tiangen Biotech(Beijing) Co., Ltd.pono e unuhi ʻia e like me nā ʻōlelo aʻoaʻo, a ʻo ka nui o ka unuhi ʻōlelo ʻia he 200 μL a ʻo ka nui elution i ʻōlelo ʻia he 160 μL.


  • Mua:
  • Aʻe:

  • E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou